[go: up one dir, main page]

SG10201400320TA - Bioconjugates made from recombinant n-glycosylated proteins from procaryotic cells - Google Patents

Bioconjugates made from recombinant n-glycosylated proteins from procaryotic cells

Info

Publication number
SG10201400320TA
SG10201400320TA SG10201400320TA SG10201400320TA SG10201400320TA SG 10201400320T A SG10201400320T A SG 10201400320TA SG 10201400320T A SG10201400320T A SG 10201400320TA SG 10201400320T A SG10201400320T A SG 10201400320TA SG 10201400320T A SG10201400320T A SG 10201400320TA
Authority
SG
Singapore
Prior art keywords
recombinant
glycosylated proteins
procaryotic cells
bioconjugates
bioconjugates made
Prior art date
Application number
SG10201400320TA
Inventor
Fabiana Fernandez
Michael Wetter
Michael Kowarik
Michael Wacker
Original Assignee
Glycovaxyn Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glycovaxyn Ag filed Critical Glycovaxyn Ag
Publication of SG10201400320TA publication Critical patent/SG10201400320TA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0283—Shigella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/104—Pseudomonadales, e.g. Pseudomonas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/105—Delta proteobacteriales, e.g. Lawsonia; Epsilon proteobacteriales, e.g. campylobacter, helicobacter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/034—Fusion polypeptide containing a localisation/targetting motif containing a motif for targeting to the periplasmic space of Gram negative bacteria as a soluble protein, i.e. signal sequence should be cleaved
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
SG10201400320TA 2008-02-20 2009-02-19 Bioconjugates made from recombinant n-glycosylated proteins from procaryotic cells SG10201400320TA (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US6416308P 2008-02-20 2008-02-20
US7154508P 2008-05-05 2008-05-05
US12948008P 2008-06-30 2008-06-30
US12985208P 2008-07-24 2008-07-24
US13668708P 2008-09-25 2008-09-25

Publications (1)

Publication Number Publication Date
SG10201400320TA true SG10201400320TA (en) 2014-05-29

Family

ID=40888413

Family Applications (1)

Application Number Title Priority Date Filing Date
SG10201400320TA SG10201400320TA (en) 2008-02-20 2009-02-19 Bioconjugates made from recombinant n-glycosylated proteins from procaryotic cells

Country Status (19)

Country Link
US (4) US8895014B2 (en)
EP (2) EP2257307B1 (en)
JP (2) JP5782258B2 (en)
KR (1) KR20100123730A (en)
CN (1) CN101983070B (en)
AU (1) AU2009215341B2 (en)
CA (1) CA2716187C (en)
CY (1) CY1120512T1 (en)
DK (1) DK2257307T3 (en)
ES (1) ES2684129T3 (en)
HR (1) HRP20181259T1 (en)
HU (1) HUE039413T2 (en)
IL (1) IL207350A (en)
LT (1) LT2257307T (en)
PL (1) PL2257307T3 (en)
PT (1) PT2257307T (en)
SG (1) SG10201400320TA (en)
SI (1) SI2257307T1 (en)
WO (1) WO2009104074A2 (en)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1481057E (en) 2002-03-07 2006-05-31 Eidgenoess Tech Hochschule SYSTEM AND METHOD FOR THE PRODUCTION OF RECOMBINANT GLYCOSILATE PROTEINS IN A PROCARIOT HOST
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
WO2005120546A2 (en) 2004-03-03 2005-12-22 Essentia Biosystems, Inc. Compositions and methods for topical diagnostic and therapeutic transport
US10105448B2 (en) 2005-01-11 2018-10-23 The United States Of America As Represented By The Secretary Of The Navy Combined enteropathogen recombinant construct
US9180081B2 (en) 2005-03-03 2015-11-10 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
PT2257307T (en) 2008-02-20 2018-10-22 Glaxosmithkline Biologicals Sa Bioconjugates made from recombinant n-glycosylated proteins from procaryotic cells
GB0915403D0 (en) * 2009-09-04 2009-10-07 London School Hygiene & Tropical Medicine Protein glycosylation
KR101855380B1 (en) 2009-11-19 2018-05-08 글락소스미스클라인 바이오로지칼즈 에스.에이. Biosynthetic system that produces immunogenic polysaccharides in prokaryotic cells
EP2545081B1 (en) 2010-02-11 2015-01-28 The Governors of the University of Alberta N-Linked Glycan Compounds
HUE037956T2 (en) 2010-05-06 2018-09-28 Glaxosmithkline Biologicals Sa Capsular gram-positive bacteria bioconjugate vaccines
CA2809890A1 (en) * 2010-09-03 2012-03-08 The Governors Of The University Of Alberta Peptide containing multiple n-linked glycosylation sequons
KR20120062457A (en) 2010-12-06 2012-06-14 삼성전자주식회사 Print circuit board for semiconductor package improving a solder joint reliablity and semiconductor package having the same
WO2013023296A1 (en) 2011-08-12 2013-02-21 The Governors Of The University Of Alberta Method of diagnosing bacterial infections using bacterial glycoproteins
EP2753353A1 (en) 2011-09-06 2014-07-16 Glycovaxyn AG Bioconjugate vaccines made in prokaryotic cells
WO2013159234A1 (en) * 2012-04-27 2013-10-31 The Governors Of The University Of Alberta Glycoengineered outer membrane vesicles and use thereof as vaccines
JP6373836B2 (en) 2012-07-26 2018-08-15 ザ・ヘンリー・エム・ジャクソン・ファンデイション・フォー・ジ・アドヴァンスメント・オヴ・ミリタリー・メディシン、インコーポレイテッド Multimeric fusion protein vaccine and immunotherapy
CN104902931A (en) * 2012-09-10 2015-09-09 格林考瓦因有限公司 Bioconjugates comprising modified antigens and uses thereof
WO2014057109A1 (en) * 2012-10-12 2014-04-17 Glycovaxyn Ag Methods of host cell modification
EP2724730A1 (en) * 2012-10-29 2014-04-30 Institut Pasteur Glycoconjugates and their use as potential vaccines against infection by Shigella Flexneri
AU2013343520B2 (en) 2012-11-07 2017-09-28 Glaxosmithkline Biologicals S.A. Production of recombinant vaccine in E. Coli by enzymatic conjugation
AU2014206799B9 (en) 2013-01-17 2018-05-10 Janssen Pharmaceuticals, Inc. MDR E. coli specific antibody
WO2014111724A1 (en) 2013-01-18 2014-07-24 London School Of Hygiene And Tropical Medicine Glycosylation method
GB201301085D0 (en) 2013-01-22 2013-03-06 London School Hygiene & Tropical Medicine Glycoconjugate Vaccine
KR20160062169A (en) * 2013-10-11 2016-06-01 글리코박신 아게 Methods of host cell modification
FI3110441T3 (en) 2014-02-24 2024-05-06 Glaxosmithkline Biologicals Sa Novel polysaccharide and uses thereof
CN106794237B (en) * 2014-04-17 2022-04-12 葛兰素史密丝克莱恩生物有限公司 Modified host cells and uses thereof
JP6590916B2 (en) * 2014-09-24 2019-10-16 ザ ユナイテッド ステイツ オブ アメリカ アズ レプレゼンティッド バイ ザ セクレタリー オブ ザ ネイビーＴｈｅ Ｕｎｉｔｅｄ Ｓｔａｔｅｓ Ｏｆ Ａｍｅｒｉｃａ Ａｓ Ｒｅｐｒｅｓｅｎｔｅｄ Ｂｙ Ｔｈｅ Ｓｅｃｒｅｔａｒｙ Ｏｆ Ｔｈｅ Ｎａｖｙ Recombinant construct of a combination of toxigenic Escherichia coli and Jejuni
US10500261B2 (en) 2014-11-05 2019-12-10 The United States Of America As Represented By The Secretary Of The Navy Synthetic antigen constructs against campylobacter jejuni
WO2016073773A1 (en) 2014-11-05 2016-05-12 The United States Of America As Represented By The Secretary Of The Navy Synthetic antigen constructs against campylobacter jejuni
CN105734001B (en) 2014-12-08 2020-04-07 中国人民解放军军事医学科学院生物工程研究所 O antigen sugar chain-extended salmonella paratyphi A and application thereof
EP3240895B1 (en) * 2014-12-30 2022-01-26 GlaxoSmithKline Biologicals S.A. Compositions and methods for protein glycosylation
EP3050973A1 (en) * 2015-01-30 2016-08-03 Jennewein Biotechnologie GmbH Fermentation process for producing monosaccharides in free form from nucleotide-activated sugars
TWI715617B (en) 2015-08-24 2021-01-11 比利時商葛蘭素史密斯克藍生物品公司 Methods and compositions for immune protection against extra-intestinal pathogenic e. coli
GB201518668D0 (en) * 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Immunogenic Comosition
CN109312379B (en) 2016-04-05 2022-04-12 科学与工业研究委员会 Multifunctional recombinant nucleotide-dependent glycosyltransferase proteins and methods for their glycosylation
GB201610599D0 (en) 2016-06-17 2016-08-03 Glaxosmithkline Biologicals Sa Immunogenic Composition
GB201615427D0 (en) * 2016-09-12 2016-10-26 London School Of Hygeine & Tropical Medicine Francisella glycoconjugate vaccines
AR109621A1 (en) 2016-10-24 2018-12-26 Janssen Pharmaceuticals Inc FORMULATIONS OF VACCINES AGAINST GLUCOCONJUGADOS OF EXPEC
CN106801029B (en) * 2017-01-22 2020-05-01 山东大学 Recombinant escherichia coli and application thereof in preparation of sugar vaccine for resisting shigella
WO2018167485A1 (en) 2017-03-15 2018-09-20 London School Of Hygiene And Tropical Medicine Whole cell vaccines
GB201704117D0 (en) 2017-03-15 2017-04-26 London School Hygiene & Tropical Medicine Oligosaccharyl Transferase polypeptide
GB201712678D0 (en) 2017-08-07 2017-09-20 Glaxosmithkline Biologicals Sa Process for the manipulation of nucleic acids
GB201721576D0 (en) 2017-12-21 2018-02-07 Glaxosmithkline Biologicals Sa Hla antigens and glycoconjugates thereof
GB201721582D0 (en) 2017-12-21 2018-02-07 Glaxosmithkline Biologicals Sa S aureus antigens and immunogenic compositions
TW202003023A (en) 2018-03-12 2020-01-16 美商詹森藥物公司 Vaccines against urinary tract infections
US11530432B2 (en) * 2018-03-19 2022-12-20 Northwestern University Compositions and methods for rapid in vitro synthesis of bioconjugate vaccines in vitro via production and N-glycosylation of protein carriers in detoxified prokaryotic cell lysates
GB201807303D0 (en) 2018-05-03 2018-06-20 London School Of Hygeine & Tropical Medicine Glyconjugate vaccines
CN113227125A (en) 2018-12-12 2021-08-06 葛兰素史密丝克莱恩生物有限公司 Modified carrier proteins for O-linked glycosylation
EP3941516A1 (en) 2019-03-18 2022-01-26 Janssen Pharmaceuticals, Inc. Bioconjugates ofe col! o-antigen polysaccharides. methods of production thereof. andmethods of use thereof
IL286467B1 (en) 2019-03-18 2025-10-01 Janssen Pharmaceuticals Inc Methods of producing bioconjugates of e. coli o-antigen polysaccharides, compositions thereof, and methods of use thereof
EP3757217A1 (en) 2019-06-27 2020-12-30 GlaxoSmithKline Biologicals S.A. Methods for protein purification
EP3770269A1 (en) 2019-07-23 2021-01-27 GlaxoSmithKline Biologicals S.A. Quantification of bioconjugate glycosylation
JP7591037B2 (en) * 2019-08-09 2024-11-27 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Mutant PGLB oligosaccharyltransferase enzyme
EP3777884A1 (en) 2019-08-15 2021-02-17 GlaxoSmithKline Biologicals S.A. Immunogenic composition
CA3168108A1 (en) 2020-01-16 2021-07-22 Janssen Pharmaceuticals, Inc. Fimh mutant, compositions therewith and use thereof
CN115697396A (en) 2020-06-18 2023-02-03 葛兰素史克生物有限公司 Shigella-tetravalent (Shigella 4V) bioconjugates
EP4171625A2 (en) 2020-06-25 2023-05-03 GlaxoSmithKline Biologicals SA Klebsiella pneumoniae o-antigen vaccine
AU2021342797B2 (en) 2020-09-17 2024-02-08 Janssen Pharmaceuticals, Inc. Multivalent vaccine compositions and uses thereof
US20230349913A1 (en) * 2020-11-30 2023-11-02 Janssen Pharmaceuticals, Inc. Analytical method for glycogonjugates using a capillary-based immunoassay system
CN116888140A (en) 2021-01-12 2023-10-13 杨森制药公司 FimH mutants, compositions thereof and uses thereof
CN117222427A (en) 2021-04-01 2023-12-12 杨森制药公司 Production of E.coli O18 bioconjugates
KR20240005684A (en) 2021-04-08 2024-01-12 얀센 파마슈티칼즈, 인코포레이티드 Bioconjugate production method
WO2023118033A1 (en) 2021-12-22 2023-06-29 Glaxosmithkline Biologicals Sa Vaccine
GB202302579D0 (en) 2023-02-23 2023-04-12 Glaxosmithkline Biologicals Sa Immunogenic composition
EP4478050A1 (en) 2023-06-12 2024-12-18 Janssen Pharmaceuticals, Inc. Method for quantifying bound acetate in glycoconjugates
WO2025032534A2 (en) 2023-08-09 2025-02-13 Glaxosmithkline Biologicals Sa Modified proteins
WO2025032535A2 (en) 2023-08-09 2025-02-13 Glaxosmithkline Biologicals Sa Modified proteins
WO2025172892A1 (en) 2024-02-16 2025-08-21 Glaxosmithkline Biologicals Sa Modified proteins and methods

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0170204B1 (en) 1984-08-01 1991-09-25 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Genetic sequences, type i interferon peptide coded by them, and these organisms producing the same
US5643758A (en) 1987-03-10 1997-07-01 New England Biolabs, Inc. Production and purification of a protein fused to a binding protein
DE69333951D1 (en) * 1992-06-18 2006-02-02 Us Gov Health & Human Serv RECOMBINANT PSEUDOMONAS EXOTOXIN WITH INCREASED ACTIVITY
AU6663294A (en) 1993-05-14 1994-12-12 Upjohn Company, The Cloned dna encoding a udp-galnac:polypeptide,n-acetylgalactos aminyltransferase
US6503744B1 (en) 1999-02-01 2003-01-07 National Research Council Of Canada Campylobacter glycosyltransferases for biosynthesis of gangliosides and ganglioside mimics
EP1399538A2 (en) 1999-03-02 2004-03-24 Human Genome Sciences, Inc. Engineering intracellular sialylation pathways
NZ522320A (en) 2000-05-12 2007-03-30 Neose Technologies Inc In vitro modification of glycosylation patterns of recombinant glycopeptides
PT1294910E (en) 2000-06-30 2009-02-16 Vib Vzw Protein glycosylation modification in pichia pastoris
PT1481057E (en) 2002-03-07 2006-05-31 Eidgenoess Tech Hochschule SYSTEM AND METHOD FOR THE PRODUCTION OF RECOMBINANT GLYCOSILATE PROTEINS IN A PROCARIOT HOST
US20040265954A1 (en) 2002-03-07 2004-12-30 Markus Aebi System and method for the production of recombinant proteins
CN1671722A (en) 2002-08-01 2005-09-21 加拿大国家研究院 Campylobacter glycans and glycopeptides
CN104356241A (en) * 2003-08-01 2015-02-18 美国政府（由卫生和人类服务部、国立卫生研究院的部长所代表） Methods for expression and purification of immunotoxins
EP2657251B1 (en) * 2004-05-24 2018-03-21 The Government of The United States of America, as represented by The Secretary, Department of Health and Human Services Live, oral vaccine for protection against Shigella dysenteriae serotype 1
CA2607595C (en) * 2005-05-11 2018-11-27 Eth Zuerich Recombinant n-glycosylated proteins from procaryotic cells
PT2257307T (en) 2008-02-20 2018-10-22 Glaxosmithkline Biologicals Sa Bioconjugates made from recombinant n-glycosylated proteins from procaryotic cells
HUE037956T2 (en) 2010-05-06 2018-09-28 Glaxosmithkline Biologicals Sa Capsular gram-positive bacteria bioconjugate vaccines

Also Published As

Publication number Publication date
US20240277824A1 (en) 2024-08-22
JP6122071B2 (en) 2017-04-26
HUE039413T2 (en) 2018-12-28
HK1155938A1 (en) 2012-06-01
CA2716187A1 (en) 2009-08-27
EP2257307B1 (en) 2018-06-06
DK2257307T3 (en) 2018-08-20
US11944675B2 (en) 2024-04-02
WO2009104074A3 (en) 2009-11-05
EP2257307A2 (en) 2010-12-08
US8895014B2 (en) 2014-11-25
LT2257307T (en) 2018-08-10
ES2684129T3 (en) 2018-10-01
CA2716187C (en) 2020-01-07
CN101983070B (en) 2016-03-30
US20210085772A1 (en) 2021-03-25
US10835592B2 (en) 2020-11-17
PL2257307T3 (en) 2018-11-30
US20110097357A1 (en) 2011-04-28
CY1120512T1 (en) 2019-07-10
JP2015187174A (en) 2015-10-29
PT2257307T (en) 2018-10-22
WO2009104074A2 (en) 2009-08-27
HRP20181259T1 (en) 2018-10-05
SI2257307T1 (en) 2018-09-28
AU2009215341A1 (en) 2009-08-27
JP2011514155A (en) 2011-05-06
US20150044254A1 (en) 2015-02-12
IL207350A (en) 2017-10-31
CN101983070A (en) 2011-03-02
AU2009215341B2 (en) 2015-03-26
EP3427749A1 (en) 2019-01-16
IL207350A0 (en) 2010-12-30
JP5782258B2 (en) 2015-09-24
KR20100123730A (en) 2010-11-24

Similar Documents

Publication Publication Date Title
IL207350A0 (en) Bioconjugates made from recombinant n - glycosylated proteins from procaryotic cells
SG10201608059VA (en) Recombinant vwf formulations
HRP20130414T1 (en) Lyophilized recombinant vwf formulations
IL202213A0 (en) Recombinant protein production in avian ebxr cells
ZA201101166B (en) Modified bovine g-csf polypeptides and their uses
IL207340A0 (en) Stabilized protein compositions
IL193721A0 (en) Polypeptide producing cells
SG10201608071YA (en) Biologically active peptides
IL267556A (en) Pharmaceutical preparation comprising recombinant hcg
IL211670A0 (en) Therapeutic protein formulations
GB2462761B (en) Protein formulation
ZA201104670B (en) Pharmaceutical composition comprising aleglitazar
GB0818065D0 (en) Immunogenic peptides and uses thereof
EP2102231A4 (en) Improved expression system for recombinant human arginase i
ZA201105784B (en) Recombinant porcine chymotrypsin
EP2254901A4 (en) Therapeutic peptides
EP2314701A4 (en) Recombinant expression vector for animal cell
GB2462726B (en) Protein expression
GB0807929D0 (en) Protein formulation
GB0803594D0 (en) Protein formulation
GB0810567D0 (en) Protein expression
GB0811893D0 (en) Protein expression